NCT07139587View on ClinicalTrials.gov

The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2028

Conditions
Gastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Iparomlimab/Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-bound paclitaxel

Iparomlimab/Tuvonralimab : 5.0mg/kg, D1, Q3W Albumin-bound paclitaxel: 260mg/m², D1, Q3W

Trial Locations (1)

050000

Hebei General Hospital, Shijiazhuang

All Listed Sponsors
lead

Qingxia Li

OTHER